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KRAS is component of Ras/MAPK signaling cascade that regu-
lates cell proliferation and cell survival. Somatic mutations in
KRAS gene are often found in tumors and affect the sensitivity
of tumors to target therapy. Mutations in codons 12 or 13 of KRAS
gene in colorectal cancer (CRC) are associated with resistance to
anti-EGFR antibodies Cetuximab and Panitumumab. The
objectives of this work were to develop PCR tests for detection
mutations in KRAS gene and analyze the frequency of mutations
in KRAS gene in CRC in Russia.
DNA sequencing by Sanger is the most common method for
mutation analysis. However, the method has a sensitivity of
20% mutant allele, which is often not sufficient for the analysis
of somatic mutations in tumors.
One of the most sensitive mutation analysis methods is allele-
specific real-time PCR. This method allows to detect 1% of
mutated DNA in the sample. This sensitivity is sufficient for anal-
ysis of mutations in tumor samples containing 2–5% or more of
tumor cells in normal tissue.
In this study we developed and compared 3 new KRAS assays
(1) real-time PCR with allele-specific primers; (2) real-time wild-
type blocking PCR with LNA (locked nucleic acid) blocker; and
(3) Sanger sequencing with LNA-blocker. First assay is a PCR test
with seven reactions using allele-specific primers for detection
and genotyping 7 mutations in 12 and 13 codons of KRAS gene.
Second assay is real-time PCR with only a single pair of primers
and LNA oligonucleotide blocker. LNA-blocker is an oligonu-
cleotide which has a wild-type sequence of codons 12 and 13
of KRAS gene. LNA-blocker binds strongly to wild-type KRAS
DNA and suppresses its amplification, but does not block ampli-
fication of mutant DNA. The real-time PCR with LNA -blocker
can detect mutant DNA but does not genotype mutation. Such
assay can be used as a simple and sensitive screening test for
mutant KRAS cases if exact genotyping of mutation is not
required. We also used LNA-blocker to increase sensitivity of
Sanger sequencing. To evaluate sensitivity and specificity of
new tests DNA standards were prepared with different ratios of
normal and mutant alleles using normal human DNA without
mutation and recombinant plasmids with mutations in KRAS
(G12C, G12S, G12R, G12V, G12D, G12A, G13D). After optimization
all three assays had sensitivity 5% of mutant alleles for the
detection of mutations in KRAS gene, using 2.5–40 ng of human
DNA.
Performance of new assays for KRAS mutations was compared
using 81 colorectal tumor samples. Before analysis relative con-
tent of tumor cells in the samples was evaluated by pathologist.
If tumor content was less than 20% in the sample then regions
with a maximum number of tumor cells were manually
macrodissected before the DNA extraction. DNA was purified
from formalin fixed paraffin embedded (FFPE) tissue using
‘‘FFPE-DNA Kit” (Biolink). All three assays had high sensitivity
(95–100%) and specificity (100%) for detection of KRAS mutations
in clinical tumor samples. Mutations of the KRAS gene were
found in 37 of 81 cases (46%) of CRC including 12 cases of muta-
tion G13D, 11 cases of G12D, 5 cases of mutation G12V, 4 cases
G12C, 3 cases of mutation G12A, 2 cases G12S, 1 case G13R. A sin-
gle case with mutation G13R wasmissed by allele-specific PCR but
was detected by real-time PCR with LNA-blocker and confirmed
by sequencing.
New assays have high sensitivity and specificity and are suit-
able for detection of KRAS mutations in clinical FFPE tumor
samples.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.076
P90
Dynamic changes of circulating microRNA expression in response to
the lung cancer combined therapy
A. Ponomaryovaa,c,*, E. Rykovab, N. Cherdyntsevaa,d, E. Morozkinb,
I. Zaporozhchenkob, T. Skvortsovab, A. Dobrodeeva, A. Zav’yalova,
S. Tuzikova, V. Vlassovb, P. Laktionovb. aTomsk Cancer Research
Institute, Tomsk, Russian Federation, b Institute of Chemical Biology and
Fundamental Medicine, SB RAS, Novosibirsk, Russian Federation,
cNational Research Tomsk Polytechnic University, Tomsk, Russian
Federation, dNational Research Tomsk State University, Tomsk,
Russian Federation
⇑
Corresponding author.
Background: The analysis of circulating tumor nucleic acids
(DNAs and RNAs) in the blood seems to be a promising approach
for the development of the low-invasive methods of tumor detec-
tion, valuable for clinical practice. Detection of oncogenic and
tumor suppressor miRNAs in the blood plasma/serum is evidence
of their participation in pathogenesis and suggest the possibility
of their use as tumor markers and targets for therapy. Thus, the
determination of expression level of tumor-associated miRNAs
in plasma can lead to significant progress in understanding the
tumor development and treatment.
Aim: Estimation the changes in expression level of miRNAs
(miR-19b, miR-25, miR-125b, miR-126, miR-205) in blood plasma
from lung cancer patients during combined therapy and to
estimate their value as disease monitoring markers.
Materials and methods: Blood samples were taken from
patients (n = 23) with non-small cell lung cancer treated at the
Tomsk Cancer Research Institute. These samples were stabilized
and fractionated into plasma and blood cells. MicroRNA was iso-
lated from blood plasma using single-phase phenol-free extrac-
tion protocol and purified on silica-based spin columns
(BioSilica Ltd, Novosibirsk, Russia). Concentration of five above
mentioned miRNAs was measured by quantitative RT-PCR and
normalized to miR-16 using dCt method.
Results: In this study we analyzed the dynamic expression
changes of circulating DNA in blood plasma from lung cancer
patients during the combined therapy. Circulating miRNAs were
isolated from plasma samples of non-small cell lung cancer
patients before treatment, within 30 days after completing
chemotherapy and 15 days after surgery, by using developed
methodological approach. In case of miR-19b and miR-125b anal-
ysis was found that the miRNA expression level correlates with
clinical response to chemotherapy and surgery. Increasing level
of miR-19b and decreasing level of miR-125b were associated with
therapeutic response. Using Repeated measures ANOVA analysis
we demonstrated that the miR-19b and miR-125b expression
levels changes throughout three check-up points during the
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combined treatment are characterized by the significant cubic
trend (P = 0.00284 and P = 0.029, respectively). Changes of
miRNA-126 expression level during post-treatment follow-up
were not characterized by the definite trend and not correlated
with changes of other miRNAs expression level. It was shown
the significant correlation between miRNA-25 and miRNA-205
expression levels, but was not found the trend of these miRNAs
level changes.
Conclusion: The clinical utility of the circulating miR-19b and
miR-125b expression analysis from this study remains to be
validated in large cohorts of patients with different histological
types of tumors, at the different stage of disease and outcomes.
One of the criteria for inclusion in the group must be susceptibil-
ity and/or resistance to therapy.
The research has been carried out with support of the grant from the
Russian Science Support Foundation 14-04-01881, Post-doctorate
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Background: Epithelial ovarian cancer frequently metastasizes
to the omentum, a process that requires pro-angiogenic activa-
tion of HOMECs by tumour -secreted factors in their microenvi-
ronment. We have previously shown that ovarian cancer cells
secrete a range of factors with possible roles in metastatic angio-
genesis including the lysosomal proteases cathepsin D (CD) and
cathepsin L (CL). However, the role of these proteases in ovarian
cancer metastasis to the omentum is not fully understood.
Aim: To investigate whether proliferative effects of CD and CL
are dependent on their catalytic activity in HOMECs.
To investigate the intracellular signalling kinases activated by
CD and CL.
Method: HOMEC proliferation was assessed by using a colori-
metric (WST1) assay. Potential signalling pathways were exam-
ined by phosphokinase array and ELISAs. pH experiments were
carried out examine whether the observed effects were due to
the catalytic activity of CD and CL.
Result: CD and CL (50 ng/ml) significantly increased HOMEC
proliferation to 141 ± 27% (p = 0.001, n = 50) and 151% ± 34%
(p = 0.001, n = 45) respectively vs. control (100%) 72 h post-
treatment. Inhibitors of CD and CL enzyme activity had no effect
on HOMEC proliferation and subsequent pH data suggest a non-
proteolytic mitogenic activity of these cathepsins. Both proteins
induced phosphorylation of ERK1/2, AKT and p38a to 2, 1.5
and 1.5 folds respectively relative to total levels (compared to
control).
Conclusion: CD and CL induced proliferation in HOMECs. CD
and CL may non- proteolytically contribute to pro-angiogenic
responses of the omental microvasculature. Induction of phos-
phorylation of proliferative kinases ERK1/2, AKTand p38a suggest
possible downstream signalling cascades of these proteins.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.078
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RCC is one of the main problems in oncourology. MiRNA
expression profiles are highly specific for malignant tumors of
different locations, and can be used to detect pathological molec-
ular biomarkers and to develop the optimal treatment for each
patient. Selection of miRNAs associated with the formation and
development of malignant tumors in the kidney was performed
using computer databases miRWalk (http://www.ma.uni-hei-del-
berg.de/apps/zmf/mirwalk/) and miRBase (http://www.mir-base.
org/). Paired samples of tumor and histologically normal tissue
from 46 patients with RCC were studied. RNAwas isolated by phe-
nol–chloroform extraction and treated with RNase-free DNase
after isolation. MiRNA expression analysis was performed by
RT-qPCR using Applied Biosystems (USA) kits: TaqMan Micro-
RNA Assays, TaqMan MicroRNA Reverse Transcription Kit,
TaqMan Fast Universal PCR Master Mix (2x). RNU6B was used
as reference miRNA. Quantity alterations of 20 microRNAs (hsa-
miR-219, -203, -148a, -129, -9, -34a, -34b, -34c-3p, -127, -193a-5p,
-191, -17, -24 -2*, -339 -3p, -212, -375, -125b, -124a, -132, -137) were
determined in samples of tumor compared to normal tissue
biopsy from the kidney of each patient. It was shown that the
expression of studied miRNAs usually decreased in RCC tumors.
The largest decrease of expression was observed for miR-129,
which expression was10–350-fold reduced in 93% of the samples
(P < 0.05) with no change of expression in the remaining 7% of
cases. MiR-375 (80% of cases,10–270-fold decrease), miR-34b
(79% of cases, 10–60-fold decrease), miR-124a (70% of cases, 10–
200-fold decrease) also frequently showed reduced expression
in tumors. In addition to the aforementioned ones, it had been
shown that expression in the tumor compared with histologically
normal tissue from the same patient was significantly decreased
in more than half of the cases for miR-125b, miR-127, miR-203,
miR-34c-3p, miR-9. Despite the fact that in 50% of cases
decreased expression of miR-9 was detected, it was the only of
studied microRNA with a significant increase in the expression
in 21% of cases in 10–160 times (P < 0.05). Associations between
the expression of investigated miRNAs and gender and age were
not noted. Dealing with each miRNA alone, we could not detect
the dependence of expression alteration of 20 selected miRNAs
from the stage or degree of tumor differentiation of the studied
RCC samples. However, the analysis of the expression profile of
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